Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Frontiers in Oncology|January 11, 2020
Development of a Prospective Data Registry System for Non-muscle-Invasive Bladder Cancer Patients Incorporated in the Electronic Patient File SystemMurat Akand, Tim Muilwijk, Jan Cornelissen, et al.
The Oncologist|March 30, 2023
Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study ResultsKim N Chi, Neil Fleshner, Vincenzo Emanuele Chiuri, et al.
The Journal of Urology|November 14, 2019
Development and External Validation of a Multiparametric Magnetic Resonance Imaging and International Society of Urological Pathology Based Add-On Prediction Tool to Identify Prostate Cancer Candidates for Pelvic Lymph Node DissectionCédric Draulans, Wouter Everaerts, Sofie Isebaert, et al.
European Journal of Cancer (Oxford, England : 1990)|November 5, 2016
Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer TrialMaria E Goossens, Maurice P Zeegers, Hendrik van Poppel, et al.
BMC Urology|March 23, 2012
Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in BelgiumMaria E Goossens, Frank Buntinx, Steven Joniau, et al.
Future Oncology (London, England)|May 2, 2020
Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomyPiet Dirix, Michiel Strijbos, Tom Van den Mooter, et al.
European Urology Oncology|January 1, 2021
Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC)Michele Marchioni, Maximilian Kriegmair, Mathias Heck, et al.
Clinical Genitourinary Cancer|May 18, 2022
Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC RegistryMargaret F Meagher, Maria C Mir, Riccardo Autorino, et al.
Frontiers in Oncology|April 17, 2023
Proposal for a Two-Tier Re-classification of Stage IV/M1 domain of Renal Cell Carcinoma into M1 ("Oligometastatic") and M2 ("Polymetastatic") subdomains: Analysis of the Registry for Metastatic Renal Cell Carcinoma (REMARCC)Margaret F Meagher, Maria C Mir, Andrea Minervini, et al.
European Urology Oncology|May 17, 2020
Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell CarcinomaEduard Roussel, Riccardo Campi, Alessandro Larcher, et al.
Pageof 4